195 related articles for article (PubMed ID: 3085495)
1. New therapies for the chronic complications of older diabetic patients.
Clements RS
Am J Med; 1986 May; 80(5A):54-60. PubMed ID: 3085495
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibitors and late complications of diabetes.
Benfield P
Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibitors and diabetic complications.
Tomlinson DR; Willars GB; Carrington AL
Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
[TBL] [Abstract][Full Text] [Related]
4. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Hotta N; Sakamoto N
Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
[No Abstract] [Full Text] [Related]
5. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
6. Complications of diabetes. Prevalence, detection, current treatment, and prognosis.
Clements RS; Bell DS
Am J Med; 1985 Nov; 79(5A):2-7. PubMed ID: 4073075
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibitors and diabetic complications.
Raskin P; Rosenstock J
Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
[No Abstract] [Full Text] [Related]
8. Aldose reductase inhibitors.
Kirchain WR; Rendell MS
Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of aldose reductase inhibitors.
Kador PF; Robison WG; Kinoshita JH
Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
[No Abstract] [Full Text] [Related]
10. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
Finegold D; Lattimer SA; Nolle S; Bernstein M; Greene DA
Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
[TBL] [Abstract][Full Text] [Related]
11. Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
MacGregor LC; Matschinsky FM
J Clin Invest; 1985 Aug; 76(2):887-9. PubMed ID: 3928685
[TBL] [Abstract][Full Text] [Related]
12. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
Bosquet F; Grimaldi A
Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
[TBL] [Abstract][Full Text] [Related]
13. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
Beyer-Mears A; Ku L; Cohen MP
Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
[TBL] [Abstract][Full Text] [Related]
14. Prevention of defects of axonal transport in experimental diabetes by aldose reductase inhibitors.
Tomlinson DR; Willars GB; Robinson JP
Drugs; 1986; 32 Suppl 2():15-8. PubMed ID: 2431858
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition.
Goldfarb S; Simmons DA; Kern EF
Trans Assoc Am Physicians; 1986; 99():67-72. PubMed ID: 3111062
[No Abstract] [Full Text] [Related]
16. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
Greene DA; Lattimer SA
Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
[TBL] [Abstract][Full Text] [Related]
18. The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors.
Gillon KR; King RH; Thomas PK
Clin Endocrinol Metab; 1986 Nov; 15(4):837-53. PubMed ID: 3096616
[No Abstract] [Full Text] [Related]
19. Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
Stribling D; Armstrong FM; Harrison HE
J Diabet Complications; 1989; 3(2):70-6. PubMed ID: 2526143
[TBL] [Abstract][Full Text] [Related]
20. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
Greene DA; Mackway AM
Diabetes; 1986 Oct; 35(10):1106-8. PubMed ID: 3019804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
